Articles

Impact of Trump's Generic Meds Initiative on Pharma

The White House's recent addition of 600 generic medications to the TrumpRx purchasing portal could reshape the pharmaceutical landscape. This article explores the implications for pharma teams and investors.

SLAS Europe 2026: What to Expect from the Premier Pharma Event

SLAS Europe 2026 is set to be a pivotal event for the pharma industry, taking place in Vienna, Austria. This article previews key takeaways, companies to watch, and essential questions for attendees.

AstraZeneca's FDA Approval: Implications for Hypertension and Fasenra

AstraZeneca secures FDA approval for hypertension, enhancing Fasenra's market potential. Discover the implications for investors and pharma teams.

Novartis Terminates CDMO Contract: Implications for Pharma

Novartis has terminated its contract with Chinese CDMO Porton, threatening legal claims. This article explores the implications for the pharma industry.

Biodefence & Biosecurity: EuropaBio's New Task Force

EuropaBio has launched a dedicated Task Force focusing on biodefence and biosecurity. This article explores its significance for the pharmaceutical sector.

Global Pharma Tech 2026: What to Expect at the Event

The Global Pharma Tech 2026 event promises to be a pivotal gathering for industry leaders. Attendees can expect valuable insights into emerging technologies and trends.

EMA's Critical Medicines Act: Implications for Pharma Investment

The EMA's recent political agreement on the Critical Medicines Act signals significant changes in drug approval processes. This article explores its implications for the pharmaceutical industry.

Global Pharma Tech 2026: Key Insights and What to Expect

The Global Pharma Tech 2026 event in London promises to be a pivotal gathering for industry leaders. Attendees can expect insights on emerging technologies and investment opportunities.

Insights from the EuropaBio Biomanufacturing Policy Summit 2026

The EuropaBio Biomanufacturing Policy Summit 2026 brought together industry leaders to discuss the future of biomanufacturing. This article outlines key takeaways and implications for pharmaceutical teams.

Eli Lilly's Community Engagement: A Game-Changer for Pharma Marketing

Eli Lilly collaborates with Caitlin Clark to enhance community sports facilities in Indianapolis, marking a significant shift in pharmaceutical marketing strategies.

Driving Impact at Launch: The Role of Medical Affairs

This article delves into the critical role of medical affairs in ensuring successful product launches in the pharmaceutical sector, highlighting key strategies and impacts.

The Future of AI in Pharma Marketing: Insights from CMI Media Group

Discover how AI is reshaping pharma marketing strategies and what it means for business teams.

How Medical Affairs Drives Impact at Launch

This article delves into the critical role of medical affairs in driving impactful pharmaceutical launches, highlighting key strategies and outcomes.

Eli Lilly and Caitlin Clark: Transforming Indianapolis Sports Courts

Eli Lilly collaborates with Caitlin Clark to revitalize sports courts in Indianapolis, fostering community engagement and health. This initiative highlights the pharmaceutical giant's commitment to social responsibility.

Daiichi and AstraZeneca's Enhertu: Early Breast Cancer Breakthrough

Daiichi and AstraZeneca's Enhertu receives dual FDA approvals for early breast cancer, marking a significant milestone in oncology. This article explores the implications for investors and pharma teams.

Daiichi and AstraZeneca's Enhertu: Dual FDA Approvals Impact Analysis

Daiichi and AstraZeneca's Enhertu has received dual FDA approvals for early breast cancer, marking a significant milestone. This article analyzes the implications for investors and pharma teams.

Novartis Terminates Contract with Porton: Legal Implications and Industry Impact

Novartis has terminated its contract with Chinese CDMO Porton, raising questions about the legal and commercial implications for the pharmaceutical industry.

NICE Approves Imfinzi for Stomach Cancer: Regulatory Update

NICE has backed the use of Imfinzi for perioperative treatment in stomach cancer, just 17 days after its UK approval. This article analyzes the regulatory update and its implications for the pharmaceutical landscape.

Global Pharma Tech 2026: Key Insights and Expectations

As the Global Pharma Tech event approaches, B2B readers can anticipate significant developments in the pharmaceutical technology landscape. This article outlines key takeaways and what to watch for during the event.

Eisai's Leqembi Sales Forecast: Insights for Pharma Investors

Eisai's Leqembi is on track for significant sales growth, with a $900M forecast. This article explores the implications for pharma investors and teams.